title: Pharmacotherapy for disorders of consciousness: are 'awakening' drugs really a possibility?
abstract: Disorders of consciousness, including the coma state, vegetative state and minimally conscious state, are among the least understood and least curable conditions in modern neurology. Structural or functional injuries may produce impairments in the neuronal circuits (the ascending reticular activating system and thalamocortical loops) responsible for maintaining the wakefulness state and awareness, associated with a change in neurotransmitter concentrations. Pharmacological agents that are able to restore the levels of neurotransmitters and, consequently, neural synaptic plasticity and functional connectivity of consciousness networks, may play an important role as drugs useful in improving the consciousness state. Currently, there is growing interest in the scientific community with regard to pharmacological agents that act on the gamma amino-butyric acid (GABA) system, such as zolpidem and baclofen, and monoamine systems, such as dopaminergic agents and some antidepressants. The purpose of this article is to provide a comprehensive overview of these potential 'awakening' drugs in patients with disorders of consciousness. The possible mechanisms by which these drugs may exert their effects in promoting recovery of consciousness are discussed, highlighting how many findings are often the result of sporadic events rather than prospective controlled trials or implementation of standard treatment guidelines.
authors.affiliation: IRCCS Centro Neurolesi "Bonino-Pulejo", Via Palermo S.S. 113, C.da Casazza, 98124, Messina, Italy, rciurleo@libero.it.
authors.forename: Rosella
authors.initials: R
authors.lastname: Ciurleo
authors.forename: Placido
authors.initials: P
authors.lastname: Bramanti
authors.forename: Rocco Salvatore
authors.initials: RS
authors.lastname: Calabrò
mesh_terms: D000928:Antidepressive Agents / Q000494:pharmacology; D003243:Consciousness / Q000187:drug effects*; D003244:Consciousness Disorders / Q000188:drug therapy* / Q000503:physiopathology; D015259:Dopamine Agents / Q000494:pharmacology; D015195:Drug Design; D006801:Humans; D018377:Neurotransmitter Agents / Q000378:metabolism; D018458:Persistent Vegetative State / Q000188:drug therapy / Q000503:physiopathology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D000928:Antidepressive Agents; D015259:Dopamine Agents; D018377:Neurotransmitter Agents; D005680:gamma-Aminobutyric Acid